Clinical Trial Update: CD19CD22 CAR-T Therapy in Patients With High-Risk B Acute Lymphoblastic Leukemia (B-ALL). [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating CD19CD22 CAR-T therapy in high-risk B-ALL, including Ph-negative ALL patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-acute Lymphoblastic Leukemia

Drugs mentioned

• CD19CD22 CAR-T therapy

Snippet

Sponsor: The First Affiliated Hospital of Soochow University | Conditions: B Acute Lymphoblastic Leukemia, Ph-Negative ALL | Phase 2 | Status: UNKNOWN